Neurosurgeon Christopher Kellner is developing a test for aneurysm detection and leading an industry-funded effort to profile blood clots from stroke patients.
The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing.
With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
The spinout expects to launch its artificial intelligence- and biomarker-based monitoring tool in the third quarter of this year.
The firm plans to seek full commercial approval for its assay, which integrates biomarker identification with a patient's electronic medical record, later this year.
Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.
BGI will study pancreatic cancer with a group at Johns Hopkins and develop a diagnostic test for preterm birth detection with Mount Sinai Hospital researchers.
Coming one year after LabCorp's acquisition of Mount Sinai's Clinical Outreach business, the new partnership will standardize lab operations at seven hospitals.